References
- Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834 - 46; http://dx.doi.org/10.1038/nrc2256; PMID: 17957189
- Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumor dormancy. Nature reviews. Clin Oncol 2013; 10:41 - 51
- Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther 2013; 21:1507 - 16; http://dx.doi.org/10.1038/mt.2013.116; PMID: 23752316
- Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, et al. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med 2013; 19:1625 - 31; http://dx.doi.org/10.1038/nm.3397; PMID: 24240185
- Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 1999; 126:13 - 9; http://dx.doi.org/10.1067/msy.1999.98849; PMID: 10418587
- Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90:5047 - 57; http://dx.doi.org/10.1210/jc.2005-0492; PMID: 15972576